Catalent and S.Biomedics Partner to Advance Development and Manufacturing of TED-A9
Thursday, February 19, 2026
Catalent and S.Biomedics have announced a strategic partnership to support the development and manufacture of TED-A9, an allogeneic pluripotent stem cell-derived dopaminergic precursor cell therapy.
TED-A9 is based on S.Biomedics’ proprietary targeted embryonic stem cell differentiation (TED) platform. The programme aims to introduce a new regenerative medicine approach for patients living with Parkinson’s disease and forms part of the company’s expanding pipeline of stem cell-based therapies.
The therapy is being developed for the treatment of Parkinson’s disease.
The collaboration will support the initiation of S.Biomedics’ first clinical study in the United States, which is planned as a pivotal trial. The partnership is intended to establish a scalable and GMP-compliant manufacturing process to enable late-stage development and prepare for potential future commercialisation.
Catalent will provide its expertise in cell therapy development, analytical services, and GMP manufacturing. The company will utilise its global network and experience in induced pluripotent stem cells (iPSC) and embryonic stem cells (ESC) to support the progression of TED-A9 from clinical development towards commercial readiness.
The agreement aims to build a robust and scalable manufacturing foundation to help accelerate the availability of this investigational therapy for patients affected by Parkinson’s disease worldwide.
Source: catalent.com
